Faculty of Medicine of Campos dos Goytacazes, Av. Alberto Torres, 217, Campos dos Goytacazes, Brazil.
Department of Pharmacology, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil.
Pharmacol Rep. 2021 Dec;73(6):1513-1519. doi: 10.1007/s43440-021-00286-4. Epub 2021 Jun 4.
In December 2019, a new variant coronavirus, SARS-CoV-2, emerged in China, which was initially described as a pneumonia of an unknown agent. The new coronavirus spreads mainly by person-to-person transmission through close contact. The pathophysiology of COVID-19 is related to a complex immune system response that varies between people and, in severe cases of the disease, is characterized by excessive responses called "cytokine storms," which are associated with complications that can lead to a state of hypercoagulation and death. Glucocorticoids and azithromycin are drugs that may be effective in the treatment. This review aims to highlight the clinical findings that demonstrate the effectiveness of glucocorticoid and azithromycin therapy in the treatment of COVID-19. To date, many drugs have been studied for use in combination therapy, and the rapid expansion of knowledge about the virology of SARS-CoV-2 generates a more accurate direction in therapy.
2019 年 12 月，一种新型冠状病毒（SARS-CoV-2）在中国出现，最初被描述为一种不明病原体引起的肺炎。新型冠状病毒主要通过密切接触的人际传播。COVID-19 的病理生理学与人体之间复杂的免疫系统反应有关，在疾病的严重病例中，其特征是称为“细胞因子风暴”的过度反应，这与可能导致高凝状态和死亡的并发症有关。糖皮质激素和阿奇霉素是可能对治疗有效的药物。本综述旨在强调临床发现，这些发现表明糖皮质激素和阿奇霉素治疗 COVID-19 的有效性。迄今为止，已经研究了许多药物用于联合治疗，而对 SARS-CoV-2 病毒学的快速扩展知识为治疗提供了更准确的方向。
